GlassScriptPhysician profile
Mark L Sarnov
NPI 1366409815
$12,747.43
in general payments reported to CMS, 2019-2025
24 companies · $4,010 in 2025
The $4,010 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.02 · 2020: $23.35 · 2021: $542 · 2022: $1,641 · 2023: $2,872 · 2024: $3,582 · 2025: $4,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,464.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,065.72 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,915.42 | 2021-2025 | Ubrelvy, Qulipta, Viberzi |
| Pfizer INC. | $1,313.03 | 2021-2025 | |
| Novo Nordisk INC | $1,130.54 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,021.26 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $964.59 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $729.63 | 2024-2025 | Repatha, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $476.31 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $401.05 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $379.14 | 2022-2025 | |
| Abbott Laboratories | $205.67 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.98 | 2022-2024 | Jardiance, Spiriva Respimat, Combivent Respimat |
| Galderma Laboratories, L.P. | $151.69 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.53 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $141.61 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $114.03 | 2022-2025 | Nuzyra, Xhance |
| Amarin Pharma, INC. | $109.89 | 2020-2021 | |
| Exact Sciences Corporation | $91.44 | 2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $84.68 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $41.66 | 2023-2025 | Veozah, Myrbetriq |
| Seqirus USA INC | $40.52 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Biohaven Pharmaceuticals, INC. | $21.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.03 | 2025 | Cobenfy |
| Vbi Vaccine (Delaware) INC. | $16.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sarnov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.